Has the U.S. Pharma Industry valuation changed over the past few years?

Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 35.9x which is lower than its 3-year average PE of 54.0x. The 3-year average PS ratio of 5.0x is lower than the industry's current PS ratio of 5.6x.

Which industries have driven the changes within the U.S. Healthcare industry?

There are no additional sub-industries under this industry.

U.S. Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 02 Jun 2026	US$2.4t	US$424.1b	US$66.3b	15.4x	35.9x	5.6x
Thu, 30 Apr 2026	US$2.2t	US$408.1b	US$66.8b	15.8x	32.4x	5.3x
Sat, 28 Mar 2026	US$2.2t	US$405.9b	US$71.7b	16.7x	31x	5.5x
Mon, 23 Feb 2026	US$2.4t	US$411.5b	US$73.9b	19.6x	32x	5.7x
Wed, 21 Jan 2026	US$2.3t	US$402.6b	US$71.5b	20.5x	31.7x	5.6x
Fri, 19 Dec 2025	US$2.2t	US$402.8b	US$71.4b	20x	30.9x	5.5x
Sun, 16 Nov 2025	US$2.1t	US$402.8b	US$71.4b	18.8x	29.5x	5.2x
Tue, 14 Oct 2025	US$1.9t	US$387.6b	US$61.0b	17.9x	31x	4.9x
Thu, 11 Sep 2025	US$1.8t	US$387.9b	US$60.9b	18.8x	29.4x	4.6x
Sat, 09 Aug 2025	US$1.6t	US$387.9b	US$60.6b	18.4x	27.1x	4.2x
Mon, 07 Jul 2025	US$1.7t	US$382.7b	US$61.3b	18.3x	28.5x	4.6x
Wed, 04 Jun 2025	US$1.7t	US$382.7b	US$61.2b	17.9x	27.7x	4.4x
Fri, 02 May 2025	US$1.8t	US$378.6b	US$63.0b	17x	29.3x	4.9x
Sun, 30 Mar 2025	US$1.8t	US$380.7b	US$41.2b	15.2x	44.8x	4.8x
Tue, 25 Feb 2025	US$1.9t	US$381.1b	US$39.0b	18.8x	48.6x	5x
Thu, 23 Jan 2025	US$1.8t	US$369.3b	US$31.2b	18.6x	56.7x	4.8x
Sat, 21 Dec 2024	US$1.8t	US$369.4b	US$31.1b	16.7x	56.8x	4.8x
Mon, 18 Nov 2024	US$1.8t	US$373.9b	US$30.5b	19.1x	58.4x	4.8x
Wed, 16 Oct 2024	US$2.0t	US$365.3b	US$23.7b	18.5x	85.7x	5.6x
Fri, 13 Sep 2024	US$2.0t	US$364.2b	US$25.5b	18.5x	79.5x	5.6x
Sun, 11 Aug 2024	US$2.0t	US$362.1b	US$22.0b	17.1x	89.6x	5.4x
Tue, 09 Jul 2024	US$2.0t	US$357.6b	US$13.8b	15.4x	141.8x	5.5x
Thu, 06 Jun 2024	US$1.9t	US$358.3b	US$14.1b	15.6x	135.7x	5.3x
Sat, 04 May 2024	US$1.8t	US$358.0b	US$13.8b	21.4x	131x	5.1x
Mon, 01 Apr 2024	US$1.9t	US$355.2b	US$22.7b	22.7x	84.2x	5.4x
Wed, 28 Feb 2024	US$1.9t	US$355.2b	US$23.8b	24.4x	80.1x	5.4x
Fri, 26 Jan 2024	US$1.8t	US$375.2b	US$33.9b	26x	51.8x	4.7x
Sun, 24 Dec 2023	US$1.7t	US$375.2b	US$33.9b	26.7x	49.3x	4.4x
Tue, 21 Nov 2023	US$1.6t	US$375.1b	US$33.9b	25.8x	48.1x	4.4x
Thu, 19 Oct 2023	US$1.7t	US$382.7b	US$44.7b	17.6x	37.5x	4.4x
Sat, 16 Sep 2023	US$1.8t	US$381.8b	US$43.9b	18x	39.9x	4.6x
Mon, 14 Aug 2023	US$1.8t	US$381.5b	US$43.9b	18.7x	40.2x	4.6x
Wed, 12 Jul 2023	US$1.7t	US$392.8b	US$60.2b	18.4x	27.5x	4.2x
Fri, 09 Jun 2023	US$1.7t	US$393.0b	US$60.5b	18.8x	28.5x	4.4x


US Market	1.58%
Healthcare	0.32%
Pharma	0.13%
Pharma	0.13%

Company	Last Price	7D	1Y	Valuation
LLY Eli Lilly	US$1.08k	1.6% +US$15.3b	44.8%	PE38.2x
CORT Corcept Therapeutics	US$70.44	17.0% +US$1.1b	-1.7%	PE162x
ELAN Elanco Animal Health	US$23.67	8.9% +US$968.9m	76.4%	PS2.4x
EWTX Edgewise Therapeutics	US$40.26	23.1% +US$813.4m	174.1%	PB8.8x
TEVA Teva Pharmaceutical Industries	US$34.64	1.7% +US$663.7m	100.7%	PE25.8x

Announcement • 15h

Corcept Therapeutics Incorporated Presents New Data From Pivotal Phase 3 ROSELLA Trial Of Lifyorli Plus Nab-Paclitaxel At ASCO 2026

Corcept Therapeutics Incorporated presented new overall survival data from its pivotal Phase 3 ROSELLA trial of Lifyorli (relacorilant) plus nab-paclitaxel in an oral presentation at the ASCO 2026 Annual Meeting. In ROSELLA, patients treated with Lifyorli combined with nab-paclitaxel experienced a 35% reduction in the risk of death compared to patients treated with nab-paclitaxel alone (hazard ratio (HR): 0.65; p-value: 0.0004), with a median overall survival of 16.0 months, compared to 11.9 months for patients receiving nab-paclitaxel alone. No biomarker testing was required. Patients in all of ROSELLA’s prespecified subgroups experienced meaningful survival benefits. The data presented at ASCO 2026 describe the overall survival benefit in patients whose treatment included a taxane-free interval of 6 months or less (HR: 0.60) and in those who received a taxane in their most recent treatment regimen (HR: 0.67). Lifyorli, in combination with nab-paclitaxel, was approved by the U.S. Food and Drug Administration (FDA) in March 2026 for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist. It is included in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) as a preferred regimen for patients with platinum-resistant ovarian cancer. In ROSELLA, the combination of Lifyorli with nab-paclitaxel was well-tolerated. Adverse events were comparable to those in the nab-paclitaxel monotherapy arm. The prescribing information for Lifyorli includes warnings and precautions for neutropenia and severe infections, adrenal insufficiency, exacerbation of conditions treated with glucocorticoids and embryo-fetal toxicity. The most common adverse reactions experienced by more than 20% of patients (including laboratory abnormalities) were decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite. ROSELLA enrolled 381 patients with platinum-resistant ovarian cancer at sites in the United States, Europe, South Korea, Brazil, Argentina, Canada and Australia. Patients were randomized 1:1 to receive either relacorilant plus nab-paclitaxel or nab-paclitaxel alone. The ROSELLA trial was conducted in collaboration with The GOG Foundation Inc. (GOG-F) (GOG-3073), the European Network of Gynaecological Oncological Trial groups (ENGOT) (ENGOT-ov72), the Asia-Pacific Gynecologic Oncology Trials Group (APGOT) (APGOT-Ov10), the Latin American Cooperative Oncology Group (LACOG) (LACOG-0223) and the Australia New Zealand Gynaecological Oncology Group (ANZGOG) (ANZGOG-221/2023). Lifyorli (relacorilant), approved in combination with nab-paclitaxel, is the first U.S. Food and Drug Administration (FDA)-approved selective glucocorticoid receptor antagonist for adults with platinum-resistant ovarian cancer. Lifyorli is an oral medication taken the day before, the day of and the day after treatment with nab-paclitaxel. There is no biomarker requirement to receive Lifyorli. Lifyorli competitively binds to the glucocorticoid receptor (GR), where it enhances chemotherapy sensitivity by inhibiting cortisol’s suppression of apoptosis – the programmed cell death that chemotherapies such as nab-paclitaxel are meant to cause. Lifyorli does not have any effect at the body’s other steroid receptors. It is included in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) as a preferred regimen for patients with platinum-resistant ovarian cancer. LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens, at least one of which included bevacizumab. LIFYORLI is contraindicated in patients receiving systemic glucocorticoids for lifesaving purposes (e.g., immunosuppression after organ transplantation) because LIFYORLI antagonizes the effect of glucocorticoids. LIFYORLI in combination with nab-paclitaxel can cause neutropenia, including febrile neutropenia and severe infections. There was one fatal event of septic shock with febrile neutropenia. Thirty-eight percent of patients initiated granulocyte colony-stimulating factor(G-CSF) during the first or second cycle of therapy. Monitor complete blood counts prior to each weekly treatment with LIFYORLI in combination with nab-paclitaxel and as clinically indicated. Based on the severity of neutropenia, delay dose, reduce dose or permanently discontinue LIFYORLI in combination with nab-paclitaxel. Consider short-acting G-CSF administration as applicable. Consider the possibility of concurrent adrenal insufficiency, particularly in the setting of serious infection. LIFYORLIis a reversible glucocorticoid receptor antagonist and can cause adrenal insufficiency. Adrenal insufficiency can occur at any time during treatment with LIFYORLI. The risk of adrenal insufficiency is increased in situations of stress, such as acute illness, infection, or surgery. Consider whether supplemental glucocorticoids are required in the perioperative period in patients who have received LIFYORLI within 30 days of surgery.

U.S. Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Eli Lilly And Company Announces Results From Phase 3 LIBRETTO-432 Clinical Trial Of Retevmo (Selpercatinib) As Adjuvant Therapy Versus Placebo In Patients With Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer

Pfizer Inc. Announces Detailed Progression-Free and Overall Survival Results from Cohort 3

New minor risk - Share price stability

Edgewise Therapeutics Sells Muscular Dystrophy Unit to Servier in Up to US$2.65 Billion Deal

Regencell Faces Class Action Over Alleged False Statements and Market Manipulation Risk

Corcept Therapeutics Incorporated Presents New Data From Pivotal Phase 3 ROSELLA Trial Of Lifyorli Plus Nab-Paclitaxel At ASCO 2026

BioNTech and Bristol Myers Squibb Report Promising Lung Cancer Trial Data for Pumitamig

Merck & Co., Inc. Grants Breakthrough Therapy Designation For Calderasib MK-1084 For First-Line Treatment Of Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C-Mutation

Johnson & Johnson Presents New Data For TECVAYLI Demonstrating Superior Progression-Free And Overall Survival In Multiple Myeloma

Labaton Keller Sucharow LLP Files Securities Class Action Against Zoetis, Inc. and Certain of Its Executives

Price target increased by 8.1% to US$41.27

Executive VP & CFO notifies of intention to sell stock

Viatris Earnings Top Expectations With 8% Revenue Growth and Guidance Reaffirmed

GH Research Advances TRD Program With Positive Phase 2b Data and US$400 Million Shelf Approval

Elanco Bets on Befrena Approval to Tap US$1.3b Dog Dermatology Market and Boost Growth